entacapone
E804592
Parkinson’s disease medication
catechol-O-methyltransferase inhibitor
nitrocatechol derivative
pharmaceutical drug
small molecule
Entacapone is a catechol-O-methyltransferase (COMT) inhibitor used as an adjunct medication in Parkinson’s disease therapy to prolong and enhance the effects of levodopa.
Statements (48)
| Predicate | Object |
|---|---|
| instanceOf |
Parkinson’s disease medication
ⓘ
catechol-O-methyltransferase inhibitor ⓘ nitrocatechol derivative ⓘ pharmaceutical drug ⓘ small molecule ⓘ |
| canBeCombinedInFixedDoseWith |
carbidopa
NERFINISHED
ⓘ
levodopa ⓘ |
| componentOfBrand | Stalevo NERFINISHED ⓘ |
| developedBy | Orion Corporation NERFINISHED ⓘ |
| doesNotCross | blood–brain barrier effectively ⓘ |
| enhancesEffectOf |
carbidopa/levodopa combination
ⓘ
levodopa ⓘ |
| hasAdverseEffect |
abdominal pain
ⓘ
diarrhea ⓘ dyskinesia ⓘ fatigue ⓘ hallucination ⓘ nausea ⓘ orthostatic hypotension ⓘ urine discoloration ⓘ vomiting ⓘ |
| hasATCCode | N04BX02 ⓘ |
| hasBrandName |
Comtan
NERFINISHED
ⓘ
Comtess NERFINISHED ⓘ |
| hasColorEffectOnUrine | brownish-orange discoloration GENERATED ⓘ |
| hasContraindication |
history of neuroleptic malignant syndrome
ⓘ
history of non-traumatic rhabdomyolysis ⓘ pheochromocytoma ⓘ |
| hasIUPACName | (E)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethyl-2-propenamide ⓘ |
| hasLegalStatus | prescription only ⓘ |
| hasMechanismOfAction | reversible inhibition of catechol-O-methyltransferase ⓘ |
| hasMolecularFormula | C14H15N3O5 ⓘ |
| hasPharmacologicalClass | COMT inhibitor ⓘ |
| hasProteinBinding | high protein binding ⓘ |
| hasRouteOfAdministration | oral ⓘ |
| hasTarget | peripheral COMT ⓘ |
| increases |
ON time in Parkinson’s disease patients on levodopa
ⓘ
duration of levodopa effect ⓘ plasma concentration of levodopa ⓘ |
| indicatedFor |
Parkinson’s disease
NERFINISHED
ⓘ
management of end-of-dose motor fluctuations in Parkinson’s disease ⓘ |
| inhibits | catechol-O-methyltransferase ⓘ |
| marketedBy | Novartis NERFINISHED ⓘ |
| metabolizedBy | glucuronidation ⓘ |
| reduces |
OFF time in Parkinson’s disease patients on levodopa
ⓘ
peripheral metabolism of levodopa ⓘ |
| takenWith | each dose of levodopa/carbidopa ⓘ |
| usedAs | adjunct to levodopa therapy ⓘ |
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.